Eli Lilly And Company (LLY): Health Care's Featured Underperformer Of The Day

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Eli Lilly and Company ( LLY) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 2.8%. By the end of trading, Eli Lilly and Company fell $1.02 (-1.8%) to $56.49 on average volume. Throughout the day, 5.5 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.7 million shares. The stock ranged in price between $56.48-$57.75 after having opened the day at $57.02 as compared to the previous trading day's close of $57.51. Other companies within the Health Care sector that declined today were: Discovery Laboratories ( DSCO), down 22.6%, Idera Pharmaceuticals ( IDRA), down 19.3%, Oxygen Biotherapeutics ( OXBT), down 13.9%, and Oramed Pharmaceuticals ( ORMP), down 11.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $65.52 billion and is part of the drugs industry. The company has a P/E ratio of 15.8, below the S&P 500 P/E ratio of 17.7. Shares are up 16.6% year to date as of the close of trading on Friday. Currently there are five analysts that rate Eli Lilly and Company a buy, four analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief